Dutch randomized trial comparing standard catheter-directed thrombolysis versus Ultrasound-accElerated Thrombolysis for thromboembolic infrainguinal disease (DUET): design and rationale by Schrijver, A.M. et al.
STUDY PROTOCOL Open Access
Dutch randomized trial comparing standard
catheter-directed thrombolysis versus
Ultrasound-accElerated Thrombolysis for
thromboembolic infrainguinal disease (DUET):
design and rationale
A Marjolein Schrijver1, Michel MPJ Reijnen2, Jacques A van Oostayen3, Rudolf PJ Tutein Nolthenius4,
Pieter HM van der Valk5, Arjan WJ Hoksbergen6, Rutger J Lely7, Bram Fioole8, Dammis Vroegindeweij9,
Marc van Leersum10, Jean-Paul PM de Vries1*
Abstract
Background: The use of thrombolytic therapy in the treatment of thrombosed infrainguinal native arteries and
bypass grafts has increased over the years. Main limitation of this treatment modality, however, is the occurrence
of bleeding complications. Low intensity ultrasound (US) has been shown to accelerate enzymatic thrombolysis,
thereby reducing therapy time. So far, no randomized trials have investigated the application of US-accelerated
thrombolysis in the treatment of thrombosed infra-inguinal native arteries or bypass grafts. The DUET study (Dutch
randomized trial comparing standard catheter-directed thrombolysis versus Ultrasound-accElerated Thrombolysis for
thrombo-embolic infrainguinal disease) is designed to assess whether US-accelerated thrombolysis will reduce
therapy time significantly compared with standard catheter-directed thrombolysis.
Methods/design: Sixty adult patients with recently (between 1 and 7 weeks) thrombosed infrainguinal native
arteries or bypass grafts with acute limb ischemia class I or IIa, according to the Rutherford classification for acute
ischemia, will be randomly allocated to either standard thrombolysis (group A) or US-accelerated thrombolysis
(group B). Patients will be recruited from 5 teaching hospitals in the Netherlands during a 2-year period. The
primary endpoint is the duration of catheter-directed thrombolysis needed for uninterrupted flow in the
thrombosed infrainguinal native artery or bypass graft, with outflow through at least 1 crural artery.
Discussion: The DUET study is a randomized controlled trial that will provide evidence of whether US-accelerated
thrombolysis will significantly reduce therapy time in patients with recently thrombosed infrainguinal native arteries
or bypass grafts, without an increase in complications.
Trial registration: Current Controlled Trials ISRCTN72676102
Background
Thrombosis of an infrainguinal bypass graft or the
native lower leg arteries has been associated with a high
rate of limb loss and significant morbidity and mortality
[1]. Traditional therapy with thrombectomy and even-
tually additional (bypass) surgery has been associated
with moderate long-term patency rates [2]. Catheter-
directed thrombolysis was introduced in the early 1980s
as a treatment option for occluded bypass grafts. This
technique has advantages that make it ideal for acute
occlusions, including avoidance of mechanical injury to
the endothelium, no need for surgical interventions and
more complete lysis of the clot in the bypass graft or
outflow arteries. Moreover, it can dissolve platelet-fibrin* Correspondence: j.vries@antoniusziekenhuis.nl
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aggregates in the microcirculation and thrombi in collat-
eral vessels [3].
A recent systematic review that included a meta-
analysis of 5 large randomized controlled trials with a
total of 1283 patients comparing surgery with thromboly-
sis in the management of acute lower limb ischemia
showed no significant difference between them in limb sal-
vage or death at 30 days, 6 months, or 1 year. However,
hemorrhagic complications and distal embolization were
more likely at 30 days in thrombolysis patients (8.8% and
12.4%, respectively) than in surgery patients [4,5].
The incidence of these complications might be
reduced by a reduction in thrombolytic therapy time. In
recent years, ultrasound (US) has been used to acceler-
ate thrombolysis. Low-intensity US-accelerated throm-
bolysis has been shown to accelerate enzymatic clot lysis
in vitro by loosening fibrin strands and thereby increas-
ing thrombus permeability and exposing more plasmi-
nogen receptors for binding, without mechanically
disrupting the clot [6-8]. The safety of this technique
has been shown in the treatment of embolic stroke [9]
and deep venous thrombosis [10]. Only two prospective
series have been published on the use of US-accelerated
thrombolysis in the treatment of thromboembolic
obstructions of native arteries and bypass grafts of the
lower extremities. In a recent study by Wissgott et al,
25 patients with acute obstructions of the native lower
limb arteries were treated with US-accelerated thrombo-
lysis. The technical success rate of 100%, and total clot
removal was achieved in 88% of the patients within
24 hours. There were no complications related to the
catheter system. At the 1-month follow-up, 2 reocclu-
sions had occurred [11]. Motarjeme et al used US-
accelerated thrombolysis in the treatment 24 arterial
occlusions and 12 venous occlusions, and complete lysis
was achieved in 23 (96%) arterial occlusions. Average
time to achieve complete lysis was 16.4 hours (range,
3-25 hours). During the 12-month follow-up, only 1
femoropopliteal graft rethrombosed. No bleeding or
other complications occurred [12].
So far, no randomized trials have focused on US-
accelerated and standard catheter-derived thrombolysis
for arterial thromboembolic disorders of the lower
limbs. The DUET (Dutch randomised trial comparing
standard catheter-directed thrombolysis versus Ultra-
sound-accElerated Thrombolysis for thromboembolic
infrainguinal disease) study is designed to compare US-
accelerated thrombolysis with standard thrombolysis in
patients with recently thrombosed infrainguinal native
arteries or bypass grafts.
Hypothesis
We anticipate that US-accelerated thrombolysis will
result in a significant reduction in thrombolysis time
(12 hours or more), without increasing the complication
rate.
Methods/Design
Study objectives
The purpose of the study is to demonstrate that US-
accelerated thrombolysis will significantly reduce (by at
least 12 hours) therapy time compared with standard
thrombolysis, without increasing complication rate.
Primary endpoint
The primary end point is the duration of catheter-directed
thrombolysis needed for uninterrupted flow in the throm-
bosed infrainguinal native artery or bypass graft with out-
flow through at least 1 crural artery.
Secondary endpoints
1. Technical success, defined as complete lysis of the
thrombus of the native artery or bypass graft, without
distal thromboembolic complications
2. Number of units of urokinase needed for uninter-
rupted flow in the thrombosed infrainguinal native
artery or bypass graft with outflow through at least 1
crural artery
3. Thrombolysis-induced hemorrhagic complications
4. Thirty-day mortality
5. Duration of hospital admission
6. Costs of hospital admission
7. Thirty-day patency of the target native artery or
bypass graft, as evidenced by magnetic resonance angio-
graphy (MRA)
8. Drop of serum fibrinogen concentration to below
1.0 g/L during procedure
9. Conversion to open surgery
10. Distal thromboembolic complications
11. Other complications
Definitions
Complete lysis: clot lysis of >95% determined by arterio-
graphic measurements of the thrombosed native arterial
segment or bypass graft [13].
Hemorrhagic complications are defined as:
• hemorrhagic complication requiring interruption or
ending of thrombolysis
• hemorrhagic complication requiring surgical
intervention
• hemorrhagic complication requiring transfusion
Rutherford classification of acute limb ischemia [14]:
Class I: Viable–not immediately threatened, no sen-
sory loss or muscle weakness, arterial Doppler signal is
audible
Class IIa: Marginally threatened–salvageable if
promptly treated, minimal sensory loss, no muscle
weakness, arterial Doppler signal is often inaudible
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Class IIb: Immediately threatened–salvageable with
immediate revascularization, sensory loss associated with
rest pain in more than the toes, mild to moderate mus-
cle weakness, arterial Doppler signal is usually inaudible.
Class III: Irreversible–major tissue loss or permanent
nerve damage inevitable if there is significant delay
before intervention, profound limb anaesthesia and
paralysis, arterial and venous Doppler signal is inaudible
Design of study
This is a multicenter 2-group parallel randomized trial.
Participating centres
Participating centers are Albert Schweitzer Hospital
Dordrecht, Free University Medical Centre Amsterdam,
Maasstad Hospital Rotterdam, Rijnstate Hospital Arn-
hem, and St. Antonius Hospital Nieuwegein.
Setting
Patients who will meet the inclusion criteria will be
enrolled from 5 teaching hospitals in the Netherlands.
Patients
A total of 60 adult patients with acute lower limb ische-
mia due to recently (between 1 and 7 weeks) throm-
bosed infrainguinal native arteries or bypass grafts will
be randomized.
Eligibility criteria
Inclusion criteria
1. Men and women older than 18 years and younger
than 85 years old
2. Patients with recently (between 1 and 7 weeks)
thrombosed femoropopliteal or femorocrural native
arteries or femoropopliteal or femorocrural venous or
prosthetic bypass grafts with ischemic complaints
3. Patients with acute lower limb ischaemia class I and
IIa according to the Rutherford classification
4. Patients understand the nature of the procedure
and provide written informed consent before enrollment
in the study
Exclusion criteria
1. Patients with isolated common femoral artery throm-
bosis, including the origin of the superficial femoral
artery and profunda femoral artery
2. Patients with localized (less than 5 cm) emboli or
occlusions in the native femoropopliteal arteries
3. Patients with clinical complaints of acute lower limb
ischemia due to thrombosis of the femoropopliteal or
femorocrural native arteries, or femoropopliteal or
femorocrural venous or prosthetic bypass grafts less
than 1 week and more than 7 weeks
4. Patients with acute lower limb ischemia class IIb
and III according to the Rutherford classification
5. Patients for whom antiplatelet therapy, anticoagu-
lants, or thrombolytic drugs are contraindicated
6. Recent (less than 6 weeks) ischemic stroke or cere-
bral bleeding
7. Patients with recent (less than 6 weeks) surgery
8. Severe hypertension (diastolic blood pressure
greater than 110 mm Hg, systolic blood pressure greater
than 200 mm Hg)
9. Current malignancy
10. Patients with a history of prior life-threatening
reaction to contrast medium
11. Patients with uncorrected bleeding disorders (gas-
trointestinal ulcer, menorrhagia, liver failure)
12. Women with child-bearing potential not taking
adequate contraceptives or currently breastfeeding
13. Pregnancy
14. Patients considered hemodynamically unstable at
the onset of the procedure
15. Patients who refuse treatment
16. Patients who are currently participating in another
investigational drug or device study who have not com-
pleted the entire follow-up period
17. Patients younger than 18 years or older than
85 years
18. Severe comorbid condition with a life expectancy
of less than 1 month
19. Contraindication for magnetic resonance imaging
(MRI)
Randomization
Central randomization will take place using a computer-
ized randomization procedure. Block-randomization is
used and stratified according to whether a native artery
or a bypass graft is involved. Blinding will not be used.
Ethics
This study is conducted in accordance with the princi-
ples of the Declaration of Helsinki and Good Clinical
Practice guidelines. The study protocol was approved
by the Ethics Committee (METC) of the St. Antonius
Hospital Nieuwegein (R-09.17A). Written informed
consent will be obtained from all patients, before
randomization.
Safety and quality control
Data Safety Monitoring Board
The Data Safety Monitoring Board (DSMB) is composed
of 4 members: 2 independent vascular surgeons and 2
independent interventional radiologists. None of the 4
members is working in one of the hospitals that will
include patients. The role of the DSMB is to review
safety and to make recommendations regarding the con-
duct of the study to the steering committee and to the
accredited METC that approved the study protocol.
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Adverse and serious adverse events
Adverse events (AE) are defined as any undesirable
experience occurring to a participant during the study,
whether or not considered related to the investigational
device. This definition includes events occurring during
hospital stay right up to 30 ± 7 days of follow-up.
Underlying disease that was present at the time of
enrollment is not reported as an AE, but any increase in
the severity of the underlying disease will be reported as
an AE.
All AEs will be monitored from the time of enrolment
through the 30-day follow-up visit. AEs can be classified
as moderate or serious and will be recorded on the case
record forms (CRFs). A description of the event, includ-
ing the start date, end date, whether device-related, any
action taken, and the outcome will be provided along
with the investigator’s assessment of the relationship
between the AE and the study treatment.
A serious adverse event (SAE) is any untoward medi-
cal occurrence or effect that at any dose results in
death, or that;
• is life-threatening at the time of the event;
• requires hospitalization or prolongation of an exist-
ing inpatient’s hospitalization;
• results in persistent or significant disability or inca-
pacity; or
• necessitates an intervention to prevent a permanent
impairment of a body function or permanent damage to
a body structure.
Clinical events to be considered and reported as SAEs
include:
• death
• myocardial infarction
• stroke
• bleeding complication requiring interruption or end-
ing of thrombolysis
• bleeding complication requiring surgical intervention
• bleeding complication requiring transfusion
A moderate adverse event (MAE) is any untoward
medical occurrence or effect that at any dose will not
lead to death, or
• life-threats,
• significant disability or incapacity,
• require hospitalization or prolongation of an existing
inpatient’s hospitalization, or
• necessitate an intervention to prevent a permanent
impairment of a body function or permanent damage to
a body structure.
Clinical events to be considered and reported as
MAEs include:
• groin hematoma,
• bleeding complication not requiring interruption or
ending of thrombolysis, surgical intervention, or
• transfusion.
Data on SAEs and MAEs will be reported to the
DSMB and to the accredited METC via the “Toetsin-
gonline” website of the website of the Central Commit-
tee on Research inv. Human Subjects (CCMO, ccmo.nl).
Statistical analysis
Intention-to-treat
The analysis will be performed in accordance with
intention-to-treat principle.
Sample size calculation
The assumption has been made that the mean duration
for successful standard thrombolytic treatment of infra-
inguinal native arteries or bypass grafts is 2.5 ± 1 day,
based on retrospective series from the St. Antonius Hos-
pital, Nieuwegein. Given a power of 90% and a 2-tailed
significance of 5%, a 2-armed randomized trial including
26 patients in each arm will be needed to prove a signif-
icant reduction in therapy time (12 hours or more) with
US-accelerated thrombolysis compared with standard
thrombolysis. Taking into account 5% to 10% dropouts
in each arm, 30 patients need to be included in each
study arm. We will analyze the primary outcome by
means of Kaplan-Meier and Log-rank test. The sample
size calculation is also based on this premise. We will
assess imbalance in prognostic factors as a secondary
analysis by means of Cox-proportional Hazards multi-
variate analysis.
An interim analysis on the primary end point (ie, effi-
cacy) will be performed after 50% of patients have com-
pleted their follow-up. The Peto approach will be
followed, meaning that the study will only be stopped
for beneficial effects in case of a P < .001 [15]. The
study will not be stopped in case of futility. End points
in blinded groups will be assessed by the DSMB.
Intervention
Group A (standard thrombolysis)
Standard thrombolysis will be performed with use of a
5F UniFuse Infusion catheter (AngioDynamics, Queens-
bury, NY, USA) with a working length of 90 cm, with
infusion holes around the circumference of the distal
10 cm to 50 cm of the catheter. Access sites may be the
contralateral common femoral artery, the ipsilateral
common femoral artery, or a brachial approach.
During the initial angiography, the catheter will be navi-
gated over a guidewire and positioned in such way that
the entire distal segment with the infusion holes is in the
thrombosed segment. At standardized intervals, a control
angiography will be performed. During each control angio-
graphy, the distal part of the thrombolysis catheter will be
repositioned in the remaining thrombosed segment.
Group B (US-accelerated thrombolysis)
US-accelerated thrombolysis involves simultaneous
delivery of low-intensity US and a thrombolytic agent
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into a thrombosed vessel. US-accelerated thrombolysis
will be performed with use of the EKOS EndoWave sys-
tem (EKOS Corporation, Bothell, WA, USA). This sys-
tem consists of a 5.2F multilumen thrombolysis delivery
catheter with a 106 cm or 135 cm working length and a
matching US coaxial core wire with a working zone of
6 cm to 50 cm. The central lumen of the multilumen
thrombolysis delivery catheter accommodates the US
core. Thrombolytics will be infused through 3 drug
lumens containing multiple side holes. Low-intensity
(2.2 MHz), high-frequency US will be delivered over the
entire length of the infusion catheter. US power and
local temperature are automatically controlled by a por-
table control unit.
During the initial angiography, a multilumen throm-
bolysis delivery catheter will be navigated over a guide-
wire into the thrombosed segment in such a way that
the US treatment zone traverses the entire thrombosed
segment and the tip of the infusion catheter is located
distal to the thrombosed segment. After final position-
ing, the guidewire will be exchanged for a matching US
core wire, and thrombolytic therapy will be started.
Likewise, a control angiography will be performed at
standardized intervals.
If placement of the EKOS system is technically not
feasible, the procedure will be defined as a technical
treatment failure. The vascular surgeon or interventional
radiologist, or both, may decide what alternative treat-
ment they will start, for instance, standard thrombolysis
or conversion to open surgery. The outcome of these
patients will be analyzed in group B according to the
intention-to-treat principles.
General
The primary angiography in groups A and B will be
started at day 1 at 8.00 a.m. ± 1 hour for logistic rea-
sons. After successful positioning of the thrombolysis
catheter, a bolus of 250,000 IU urokinase is given and
followed by a continuous infusion with a dose of
100,000 IU urokinase/h. A control angiography will be
performed every 6 ± 1 hours. During the night, standard
angiography will only be performed in emergencies.
Angiographies will be performed the next day at 8.00 a.m.
± 1 hour; 2.00 p.m. ± 1 hour, and 8.00 p.m. ± 1 hour.
A checklist is completed during each angiography.
The pressure curve from the EKOS monitor will be
recorded constantly from the start of the procedure.
From the start of thrombolysis until completion angio-
graphy, the ankle-brachial indices of the treated leg and
a standardized pain score will be recorded every 3 hours
by a nurse practitioner or surgical resident. Every day
during thrombolysis, the fibrinogen concentration must
be checked: if <1.0 g/L the urokinase rate must be low-
ered to 50,000 IU/h; if the fibrinogen concentration is
<0.5 g/L, thrombolysis must be stopped. If the
obstructive clot has been successfully thrombolized, any
necessary additional procedure, for instance percuta-
neous transluminal angioplasty (PTA) of the inflow or
outflow artery, is performed before the completion
angiography, and again, a checklist of the last angiogra-
phy is completed.
After successful thrombolysis, systemic heparin is
given (25,000 IU/24 hours) and coumarin derivatives are
started. Activated partial thromboplastin time (aPTT)
will be measured daily during heparinization. The target
international normalized ratio (INR) will be 2.5 to 3.5; if
this value is reached, heparinization can be stopped.
Data collection
Data will be collected by means of a CRF during treat-
ment in the participating centers. The CRF will be com-
pleted prospectively during hospital admission and
during follow-up. After that, the CRFs will be forwarded
to the data coordinating center. There will be regular
contact between the study coordinators and the partici-
pating centers.
Follow-up
Patients are followed-up during their hospital stay. At 30
± 7 days after thrombolysis has been completed, there is
one follow-up visit in the outpatient department, includ-
ing a physical examination, ankle-brachial index, tread-
mill test, and contrast-enhanced MRA of the treated leg,
according to current guidelines [16]. During follow-up,
any additional procedures, conversion to open surgery,
duration and costs of hospital admission, death, distal
thromboembolic complications, and other complications
will be recorded.
Discussion
Several treatment strategies have focused on accelerating
thrombolytic therapy to improve its effectiveness and to
reduce treatment time and, therefore, adverse effects.
US-accelerated thrombolysis, which involves the simul-
taneous delivery of low-intensity US and a thrombolytic
agent into a thrombosed vessel, has been shown to
reduce therapy time. The DUET study is designed to
compare US-accelerated thrombolysis with standard
thrombolysis in patients with recently thrombosed infra-
inguinal native arteries or bypass grafts.
Only patients with acute lower limb ischemia in class I
and IIa, according to the Rutherford classification, will
be included in our study, because catheter-directed
thrombolysis is the initial treatment chosen in patients
with viable or minimally threatened lower limbs.
Immediate surgical revascularization is indicated in
most patients with acute lower limb ischemia class IIb
and III; therefore, these patients will be excluded from
the study.
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Prolonged thrombolysis therapy might be expected in
clots older than 1 week. Most clots that are less than 1
week old can be rather easily and quickly treated with
standard catheter-directed thrombolysis or thrombosuc-
tion. The additional value of the more expensive US-
accelerated thrombolysis in these thrombi may be
argued and these are therefore excluded from this study.
Randomization is stratified according to whether a
native artery or a bypass graft is occluded, because it has
been shown that thrombolysis of a bypass graft will lead
to better outcome than thrombolysis of a native artery.
To test our hypothesis, a control angiography should
be performed every 12 hours. Therefore, our sample
size calculation is based on a reduction in therapy time
of 12 hours or more. Control angiographies at 8:00 a.m.
and at 8.00 p.m. would have been sufficient. However,
in our study protocol we have incorporated an extra
control angiography at 2.00 p.m. to measure our pri-
mary outcome more precisely and to reduce any unne-
cessary exposure to thrombolytics in our study
participants.
Two vascular surgeons and 2 interventional radiolo-
gists from 2 nonparticipating centers will review all
angiographies independently. The vascular surgeons and
the interventional radiologists will be blinded for patient
characteristics and for the results of the initial reports.
They will be asked to classify the degree of lysis, ranging
from no lysis, partial lysis, to complete lysis (>95% lysis).
If thrombolysis of the occluded segment is successful,
any hemodynamically significant underlying athero-
sclerotic lesion will be identified and treated. Preferably,
the underlying lesion will be treated endovascularly,
with PTA with or without stent placement, or both. It
will be the vascular surgeon’s or interventional radiolo-
gists’ decision to convert to open surgery if endovascular
treatment of the underlying lesion is not feasible or if
thrombolysis of the occluded segment is not successful.
Conclusion
The DUET study is a randomized controlled trial that
will provide evidence whether US-accelerated thrombo-
lysis will significantly reduce therapy time compared
with standard thrombolysis in patients with recently
thrombosed infrainguinal native arteries or bypass grafts,
without an increase in the number of complications.
Appendix
DUET committee members
Steering committee
JPPM de Vries (chairman), AM Schrijver (principal
investigator), M van Leersum, St. Antonius Hospital,
Nieuwegein; MMPJ Reijnen, Rijnstate Hospital, Arnhem.
Monitoring Committee
GJ de Borst (chairman), EJ Vonken, UMC Utrecht; BP
Keller, H Alkefaji, Martini Hopsital, Groningen.
Acknowledgements
The authors wish to acknowledge the support of Johannes C. Kelder, who
assisted in the sample size calculation for this study. AngioCare, Eemnes,
funded part of the follow-up of this study.
Author details
1Department of Surgery, St. Antonius Hospital Nieuwegein, The Netherlands.
2Department of Surgery, Rijnstate Hospital Arnhem, The Netherlands.
3Department of Radiology, Rijnstate Hospital Arnhem, The Netherlands.
4Department of Surgery, Albert Schweitzer Hospital Dordrecht, The
Netherlands. 5Department of Radiology, Albert Schweitzer Hospital
Dordrecht, The Netherlands. 6Department of Surgery, Free University Medical
Centre Amsterdam, The Netherlands. 7Department of Radiology, Free
University Medical Centre Amsterdam, The Netherlands. 8Department of
Surgery, Maasstad Hospital Rotterdam, The Netherlands. 9Department of
Radiology, Maasstad Hospital Rotterdam, The Netherlands. 10Department of
Radiology, St. Antonius Hospital Nieuwegein, The Netherlands.
Authors’ contributions
AMS and JPPMdV drafted the manuscript.
AMS, MMPJR, RPJTN, AWJH, MvL and JPPMdV participated in the design of
the study.
All authors edited the manuscript and read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 23 July 2010 Accepted: 23 January 2011
Published: 23 January 2011
References
1. Yeager RA, Moneta GL, Taylor LM Jr, Hamre DW, McConnell DB, Porter JM:
Surgical management of severe acute lower extremity ischemia. J Vasc
Surg 1992, 15:385-391.
2. Graor RA, Risius B, Young JR, Lucas FV, Beven EG, Hertzer NR, et al:
Thrombolysis of peripheral arterial bypass grafts: surgical thrombectomy
compared with thrombolysis. A preliminary report. J Vasc Surg 1988,
7:347-355.
3. Gardiner GA Jr, Harrington DP, Koltun W, Whittemore A, Mannick JA,
Levin DC: Salvage of occluded arterial bypass grafts by means of
thrombolysis. J Vasc Surg 1989, 9:426-431.
4. van den Berg JC: Thrombolysis for acute arterial occlusion. J Vasc Surg
2010.
5. Berridge DC, Kessel DO, Robertson I: Surgery versus thrombolysis for
initial management of acute limb ischaemia [Systematic Review].
Cochrane Database of Systematic Reviews 2009, 1.
6. Braaten JV, Goss RA, Francis CW: Ultrasound reversibly disaggregates
fibrin fibers. Thromb Haemost 1997, 78:1063-1068.
7. Hardig BM, Persson HW, Olsson SB: Low-energy ultrasound exposure of
the streptokinase molecule may enhance but also attenuate its
fibrinolytic properties. Thromb Res 2006, 117:713-720.
8. Siddiqi F, Odrljin TM, Fay PJ, Cox C, Francis CW: Binding of tissue-
plasminogen activator to fibrin: effect of ultrasound. Blood 1998,
91:2019-2025.
9. Tsivgoulis G, Eggers J, Ribo M, Perren F, Saqqur M, Rubiera M, et al: Safety
and efficacy of ultrasound-enhanced thrombolysis: a comprehensive
review and meta-analysis of randomized and nonrandomized studies.
Stroke 2010, 41:280-287.
10. Parikh S, Motarjeme A, McNamara T, Raabe R, Hagspiel K, Benenati JF, et al:
Ultrasound-accelerated thrombolysis for the treatment of deep vein
thrombosis: initial clinical experience. J Vasc Interv Radiol 2008,
19:521-528.
Schrijver et al. Trials 2011, 12:20
http://www.trialsjournal.com/content/12/1/20
Page 6 of 7
11. Wissgott C, Richter A, Kamusella P, Steinkamp HJ: Treatment of critical
limb ischemia using ultrasound-enhanced thrombolysis (PARES Trial):
final results. J Endovasc Ther 2007, 14:438-443.
12. Motarjeme A: Ultrasound-enhanced Thrombolysis. J Endovasc Ther 2007,
14:251-256.
13. Ouriel K, Veith FJ, Sasahara AA: A comparison of recombinant urokinase
with vascular surgery as initial treatment for acute arterial occlusion of
the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS)
Investigators. N Engl J Med 1998, 338:1105-1111.
14. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al:
Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997, 26:517-538.
15. Ellenberg SS, F T, D D: Data monitoring committees in clinical trials: a
practical perspective Chichester: John Wiley & Sons; 2002.
16. Dormandy JA, Rutherford RB: Management of peripheral arterial disease
(PAD). TASC Working Group. TransAtlantic Inter-Society Consensus
(TASC). J Vasc Surg 2000, 31:S1-S296.
doi:10.1186/1745-6215-12-20
Cite this article as: Schrijver et al.: Dutch randomized trial comparing
standard catheter-directed thrombolysis versus
Ultrasound-accElerated Thrombolysis for thromboembolic infrainguinal
disease (DUET): design and rationale. Trials 2011 12:20.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Schrijver et al. Trials 2011, 12:20
http://www.trialsjournal.com/content/12/1/20
Page 7 of 7
